All In Biotech

Drug Trial Radar · NCT06868485

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Wayshine Biopharm, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • WSD0922-FU Tablets, Dose level ADrug

    Oral, 21 days in each cycle

  • WSD0922-FU Tablets, Dose level BDrug

    Oral, 21 days in each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: every 8 weeks, up to 1 year

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Cleveland Clinic Weston Hospital

    Weston, Florida · Recruiting

  • Hackensack Meridian Health-Southern Ocean Medical Center

    Manahawkin, New Jersey · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • TxO Central/South, Texas Oncology -Central/South Texas

    Austin, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Wuhan Union Hospital

    Wuhan, Hubei, China · Recruiting

  • Shanghai East hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou

    Rennes, Ille-et-Vilaine, France · Recruiting

  • Centre Hospitalier Universitaire CHU De Limoges

    Limoges, New Aquitaine, France · Recruiting

  • CHU Bordeaux - Centre Francois Magendie

    Pessac, New Aquitaine, France · Recruiting

  • Centre Francois Baclesse

    Caen, Normandy, France · Recruiting

  • CHU Toulon - Hopital Sainte Musse

    Toulon, Var, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.